Comparative efficacy and safety of pharmacological interventions for the treatment of long COVID in adults: a systematic review and network meta-analysis

Authors:
Preprint
Publisher website
Google Scholar
Abstract
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, represents a major global pandemic of the 21st century, with long-term effects termed long COVID. This systematic review and network meta-analysis (NMA) evaluated pharmacological interventions for adults with long COVID, incorporating randomized controlled trials and adjusted observational studies. Primary outcomes included all-cause mortality, hospitalization, ICU admission, and mechanical ventilation; secondary outcomes covered symptom recovery across five categories, with safety assessed via adverse events. Results from random-effects models showed that saline nasal irrigation (SMD=21.10, 95% CI [16.91, 25.30]), nitrilotriacetic acid trisodium (SMD=7.40 [5.79, 9.01]), tetra sodium pyrophosphate (SMD=3.69 [2.61, 4.77]), and sodium gluconate (SMD=3.01 [1.92, 4.09]) significantly improved anosmia versus control. For thrombosis, rivaroxaban reduced arterial (OR=0.33 [0.01, 8.19]) and venous thrombotic events (OR=0.12 [0.01, 0.97]), while therapeutic-dose anticoagulants lowered thrombotic risks but increased major bleeding events (OR=1.86 [1.19, 2.89]) compared to prophylactic dosing. This NMA provides comparative evidence to guide treatment strategies for long COVID, highlighting the need for further research as new evidence emerges.
All Related Versions

This publication has 126 references indexed in Scilit: